Christopher J. Del Nagro
Roche (Switzerland) · 53 works · 1,830 citations · h-index 12
Top works
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity
- Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
- CD19 Function in Central and Peripheral B-Cell Development
- Suppression of Phosphatidylinositol 3,4,5-Trisphosphate Production Is a Key Determinant of B Cell Anergy
- Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
- Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development
- A Critical Role for Complement C3d and the B Cell Coreceptor (CD19/CD21) Complex in the Initiation of Inflammatory Arthritis
- Depletion of the Central Metabolite NAD Leads to Oncosis-mediated Cell Death
- Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys
- Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death
- Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody–Drug Conjugate
- Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
- Comparison of B Cell Depletion Mediated by Intravenous (IV) Rituxan® and Rituxan Given Subcutaneous (SC) In Cynomolgus Monkeys
- Abstract C150: Depletion of cellular NAD using the NAMPT inhibitor GNE-617 leads to oncosis blister cell death.
- Supplementary Table 4 from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
- Supplementary Figure 2 from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
- Supplementary Table S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
- Supplementary Table 1 from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
- Supplementary Figure S3 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
- Supplementary Methods S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors